Cardiovascular Manifestations of COVID-19
Clara Health

Cardiovascular Manifestations of COVID-19

Sponsored by Memorial Hermann Health System


Although COVID-19 manifests primarily as a respiratory illness, several cardiovascular implications have been reported related to its natural course and treatment. Its exact effect on the cardiovascular system though is currently unknown.

Cardiovascular disease associated with COVID-19 might be contributing to the high mortality rates and its recognition will allow for prevention, early diagnosis and appropriate treatment. This will be the first, large, case-control study assessing cardiovascular involvement of COVID-19 in a well-defined cohort of patients.

About 
COVID-19

Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.

How is this study designed?

Study Type: Observational Estimated Enrollment: 500 participants Actual Study Start Date: March 30, 2020 Estimated Study Completion Date: March 2022

Who is this study for?

Study Population

  • Subjects admitted to the COVID unit and medical intensive care unit of Memorial Hermann Hospital/Texas Medical Center from March 30th, 2020 to March 30th, 2021 will be identified by location search of the electronic medical records.

Inclusion Criteria:

  • Patients admitted to the hospital with symptoms of fever, sore throat, cough, nasal congestion and/or dyspnea who were tested positive for SARS-CoV-2 by PCR

Exclusion Criteria:

  • Patients of high clinical suspicion for COVID-19 with only one negative PRC test for SARS-CoV-2
  • Patients with COVID-19 who do not require hospitalization

What should I expect?

The electronic medical charts of the study subjects will be reviewed and relevant demographic, clinical, laboratory and imaging findings will be deidentified and recorded. Since our study will be a retrospective chart review study it carries minimal risk for the patients and the investigators.

Have questions or need help?

For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.